TY - JOUR
T1 - Modelling chemotherapy-induced cardiotoxicity by human pluripotent stem cells
AU - Madonna, Rosalinda
AU - Cadeddu, Christian
AU - Deidda, Martino
AU - Spallarossa, Paolo
AU - Zito, Concetta
AU - Mercuro, Giuseppe
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Novel antineoplastic therapies have greatly improved cancer survival; nevertheless they are bringing in new forms of cardiomyopathy, that can often limit proper cancer treatments. Novel cardioprotective therapies are therefore needed, for improving clinical outcomes in cancer patients. In order to test novel therapeutic strategies, there is an increasing need for appropriate experimental models of chemotherapy-induced cardiomyopathy. Induced pluripotent stem (iPS) cell- and human embryonic stem cell (hESC)-derived cardiomyocytes may be used as alternative in vitro models for studying mechanisms that underly chemotherapy-induced cardiomyopathy. In this review we discuss the use of iPS- and hESC-derived cardiomyocytes for evaluating additional pharmacological targets and for predicting chemotherapy-induced cardiotoxicity.
AB - Novel antineoplastic therapies have greatly improved cancer survival; nevertheless they are bringing in new forms of cardiomyopathy, that can often limit proper cancer treatments. Novel cardioprotective therapies are therefore needed, for improving clinical outcomes in cancer patients. In order to test novel therapeutic strategies, there is an increasing need for appropriate experimental models of chemotherapy-induced cardiomyopathy. Induced pluripotent stem (iPS) cell- and human embryonic stem cell (hESC)-derived cardiomyocytes may be used as alternative in vitro models for studying mechanisms that underly chemotherapy-induced cardiomyopathy. In this review we discuss the use of iPS- and hESC-derived cardiomyocytes for evaluating additional pharmacological targets and for predicting chemotherapy-induced cardiotoxicity.
KW - Cardiac stem cells
KW - Chemotherapy-induced cardiotoxicity
KW - Pluripotent stem cells
KW - Preclinical models
UR - http://www.scopus.com/inward/record.url?scp=84995576478&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84995576478&partnerID=8YFLogxK
U2 - 10.2174/1389450117666160401125404
DO - 10.2174/1389450117666160401125404
M3 - Review article
C2 - 27033187
AN - SCOPUS:84995576478
VL - 17
JO - Current Drug Targets
JF - Current Drug Targets
SN - 1389-4501
IS - 16
ER -